Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-008-0877-5PMID 19039589
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

  2007cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins

  2007cited by this paper
• Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

  2007cited by this paper
• Posttranslational modifications of Bcl2 family members--a potential therapeutic target for human malignancy.

  2006cited by this paper
• Targeting multidrug resistance in cancer

  2006influential reference
• βIII-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability*

  2005cited by this paper
• Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

  2005cited by this paper
• Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

  2005influential reference
• Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

  2005cited by this paper
• Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

  2004cited by this paper
• Microtubule-targeted anticancer agents and apoptosis

  2003cited by this paper
• Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

  2003cited by this paper
• The role of ABC transporters in clinical practice.

  2003cited by this paper
• Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2.

  2001cited by this paper
• Predicting the clinical status of human breast cancer by using gene expression profiles

  2001cited by this paper
• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

  2000cited by this paper
• Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.

  2000cited by this paper
• Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells.

  1998cited by this paper
• Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer.

  1998cited by this paper
• Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas.

  1998cited by this paper
• Modulation of Protein Kinases and Microtubule-associated Proteins and Changes in Ultrastructure in Female Rat Pituitary Cells: Effects of Estrogen and Bromocriptine

  1997cited by this paper
• Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

  1996cited by this paper
• Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

  1995cited by this paper
• Drug therapy : paclitaxel (Taxol)

  1995cited by this paper
• Paclitaxel (taxol)

  1995cited by this paper
• Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

  1995cited by this paper
• Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

  1993cited by this paper
• Estrogen-enhanced neurite growth: evidence for a selective induction of Tau and stable microtubules

  1991cited by this paper
• Taxol: mechanisms of action and resistance.

  1986cited by this paper
• Taxol: Mechanisms of Action and Resistance a

  1986cited by this paper
• [Treatment of metastatic breast cancer].

  1986cited by this paper

• Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease

  2024cites this paper
• RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage

  2022cites this paper
• Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma

  2022cites this paper
• An update on paclitaxel treatment in breast cancer

  2022cites this paper
• Dichotomous Role of Microtubule Associated Protein Tau as a Biomarker of Response to and a Target for Increasing Efficacy of Taxane Treatment in Cancers of Epithelial Origin.

  2021cites this paper
• Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies

  2020cites this paper
• TAU PROTEIN AS GLIAL TUMORS MARKER: A RETROSPECTIVE STUDY

  2020cites this paper
• Novel Functions of the Neurodegenerative-Related Gene Tau in Cancer

  2019influential citation
• PREDICTIVE AND PROGNOSTIC VALUES OF HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α AND TAU- PROTEIN EXPRESSION IN SEROUS OVARIAN CANCER (SOC) PATIENTS TREATED WITH CHEMOTHERAPY

  2018cites this paper
• Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption

  2018cites this paper
• Cytotoxicity of Tanshinone IIA combined with Taxol on drug‐resist breast cancer cells MCF‐7 through inhibition of Tau

  2018cites this paper
• Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy

  2017cites this paper
• Breast cancer intrinsic subtypes: a critical conception in bioinformatics

  2017cites this paper
• Treatment regimens of classical and newer taxanes

  2016cites this paper
• Predictive and prognostic value of SALL4 and Tau protein in serous ovarian cancer patients treated with chemotherapy.

  2016cites this paper
• Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning

  2016cites this paper
• Prognostic role of excision repair cross complementing-1 and topoisomerase-1 expression in epithelial ovarian cancer.

  2016cites this paper
• Linking the immunophilin FKBP 5 to taxol resistance in ovarian cancer

  2015cites this paper
• Three-Dimensional Collagen Type I Matrix Up-Regulates Nuclear Isoforms of the Microtubule Associated Protein Tau Implicated in Resistance to Paclitaxel Therapy in Ovarian Carcinoma

  2015cites this paper
• Metabolism of the taxanes including nab-paclitaxel

  2015cites this paper
• The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set

  2015cites this paper
• Linking the immunophilin FKBP5 to taxol resistance in ovarian cancer

  2015cites this paper
• Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

  2015cites this paper
• Predictive and Prognostic Value of the TauProtein in Breast Cancer.

  2015cites this paper
• Microtubule segment stabilization by RASSF1A is required for proper microtubule dynamics and Golgi integrity

  2014cites this paper
• Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer

  2014cites this paper
• Oncogenes and Tumor Suppressor Genes as a Biomarker in Breast Cancer

  2014cites this paper
• Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.

  2014cites this paper
• Predictive Biomarkers for Antibody–Drug Conjugates

  2013cites this paper
• Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy

  2013cites this paper
• Microtubule-Associated Protein Tau, α-Tubulin and βIII-Tubulin Expression in Breast Cancer

  2013cites this paper
• Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes

  2013cites this paper
• Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

  2013cites this paper
• Antimitotic inhibitors.

  2012cites this paper
• Posttranslational Modifications of Tubulin

  2012cites this paper
• Cytoskeleton and Human Disease

  2012cites this paper
• Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

  2011cites this paper
• Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens.

  2011cites this paper
• Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens

  2011cites this paper
• The role of Tau protein in resistance to paclitaxel

  2011cites this paper
• The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer

  2011cites this paper
• Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

  2011cites this paper
• A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

  2010cites this paper
• Microtubules and resistance to tubulin-binding agents

  2010cites this paper
• Microtubules and resistance to tubulin-binding agents

  2010cites this paper
• Chemotherapy: updates and new perspectives.

  2010cites this paper
• HER2 and tau expression as potential markers for response and survival to first line taxane plus cisplatin therapy in non‐small cell lung cancer

  2009cites this paper
• Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer

  2009cites this paper